Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer: Results from the I-SPY 2 Trial


This presentation is the intellectual property of I-SPY. Contact rmanda@medicine.bsd.uchicago.edu for permission to reprint and/or distribute.
Pembrolizumab and Breast Cancer

• Tumors can co-opt the PD-1 pathway to evade immune surveillance\(^1\)

• Pembrolizumab is a humanized monoclonal antibody against PD-1; modest single agent activity in heavily pretreated breast cancer
  – RR in TNBC < 10\(^%\)^\(^2\); in HR+ disease 12.0\(^%\)\(^3\)

• Safety of pembrolizumab plus paclitaxel available prior to inclusion:
  – KEYNOTE 021 trial in advanced NSCLC\(^4\)

• The I-SPY 2 Trial tested the ability of pembrolizumab to improve pathologic complete response (pCR) rates over standard therapy

The I-SPY 2 TRIAL Standing Platform

• Phase II, adaptively-randomized neoadjuvant trial
  – Goal: efficiently identify promising agents to take to phase III

• Multiple concurrent experimental arms; 13 agents to date

• Adaptive randomization minimizes number of patients needed to determine efficacy

• “Graduation” for efficacy = reach an 85% predicted probability of success in a 1:1 randomized 300 patient phase III trial
Trial Enrollment Overview

Registered (n=2048)
- Actively Being Screened (n=37)
- Did Not Proceed to the Treatment Phase (n=840)

Randomized (n=1171)

Completed Surgery (n = 1020)

Status as of June 1st, 2017
I-SPY 2 TRIAL Eligibility

**Screening**

- Tumor size > 2.5 cm
- Candidate for preoperative chemotherapy
- Study MRI and biopsy
- MammaPrint (MP)
- Adequate organ function, PS<2
I-SPY 2 TRIAL Eligibility

Screening Consent → Assess Eligibility → Core Biopsy

Hormone Receptor Positive and MammaPrint Low Risk

I-SPY2 LOW RISK REGISTRY

NOT ELIGIBLE
I-SPY 2 TRIAL Eligibility

Screening Consent → Assess Eligibility → Core Biopsy

HER2+ (IHC, FISH, TargetPrint)
Triple negative
HR+, MP High Risk

Randomized
Consented to Assigned Arm

ELIGIBLE
Primary Endpoint: pCR

• Defined as no residual invasive cancer in the breast or lymph nodes (ypT0/is and ypN0)
  – Intent-to-treat
  – Protocol-defined non-pCR:
    • Switch to non-protocol assigned therapy (e.g. addition of carbo)
    • No surgery
    • Withdrawal from the trial

• Pembrolizumab was studied in 3 HER2 negative “biomarker signatures”
  – All HER2-
  – HR+/HER2-
  – HR-/HER2- (triple-negative breast cancer; TNBC)
I-SPY 2 TRIAL Schema: HER2- Signatures

Adaptive Randomization

Paclitaxel

Paclitaxel + Pembro

Other HER2- Arms

Doxorubicin Cyclophosphamide

MRI, Blood Core Biopsy

MRI, Blood Core Biopsy

MRI, Blood

MRI, Blood Tissue

12 weeks

8-12 weeks

S U R G E R Y
I-SPY 2 Adaptive Randomization

Randomization
(Probabilities based on performance of each drug within each subtype)

Outcome
MRI→pCR model

Update probabilities

New patient accrues; assess subtype
Not Every Regimen Graduates for Efficacy

Drop for Toxicity

0% 10% 85% 100%

Drop for Futility
Toxicity

Maximum accrual reached
(n=75 Her2-) > STOP

Graduate for Efficacy

DSMB meets monthly
I-SPY 2 TRIAL Schema: HER2- Signatures

Adaptive Randomization

Paclitaxel

Paclitaxel + Pembro

Other HER2- Arms

Doxorubicin
60 mg/m2
Cyclophosphamide
600 mg/m2 X 4

12 weeks

8-12 weeks

Control
Paclitaxel 80 mg/m2 every wk x 12

Experimental
Paclitaxel 80 mg/m2 every wk x 12
Pembro 200 mg every 3 wks x 4
## Demographics

<table>
<thead>
<tr>
<th>Patient Characteristic</th>
<th>Pembrolizumab (n=69)</th>
<th>Control (n=180)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Median Age, yrs (range)</strong></td>
<td>50 (27-71)</td>
<td>47 (22-77)</td>
</tr>
<tr>
<td><strong>Race, %</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>81.2</td>
<td>76.7</td>
</tr>
<tr>
<td>African American</td>
<td>8.7</td>
<td>14.4</td>
</tr>
<tr>
<td>Asian</td>
<td>4.3</td>
<td>7.2</td>
</tr>
<tr>
<td>Other</td>
<td>5.8</td>
<td>1.7</td>
</tr>
<tr>
<td><strong>HR Status, %</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>58.0</td>
<td>52.8</td>
</tr>
<tr>
<td>Negative</td>
<td>42.0</td>
<td>47.2</td>
</tr>
<tr>
<td><strong>Median tumor size, cm (range)</strong></td>
<td>3.6 (1.9-13.0)</td>
<td>3.95 (1.2-15.0)</td>
</tr>
<tr>
<td><strong>Nodal Status</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>37.7</td>
<td>43.9</td>
</tr>
<tr>
<td>Negative</td>
<td>52.2</td>
<td>50.5</td>
</tr>
<tr>
<td>Missing</td>
<td>10.1</td>
<td>5.6</td>
</tr>
</tbody>
</table>
I-SPY 2 Results Reporting

• The I-SPY 2 Bayesian model generates predictive probability distributions of pCR rates by signature
  – Estimated pCR rates
  – Actual pCR rates not reported; biased by the adaptive randomization

• Format of results presented
  – Estimated mean pCR rates by signature
  – Probability that experimental arm is superior to the control for a given signature
  – Predicted probability of success in a 1:1 randomized 300 patient phase 3 trial
Results Format: Estimated Probabilities for pCR

Distribution of pCR Rates

- Curves: probability distribution of pCR rate
- Blue=control; Red=experimental arm
- Midpoint of curves: estimated pCR rate
- Separation: strength
- Width: certainty
Pembrolizumab graduated in all HER2- signatures: Both HR+/HER2- and TN

<table>
<thead>
<tr>
<th>Signature</th>
<th>Estimated pCR rate (95% probability interval)</th>
<th>Probability pembro is superior to control</th>
<th>Predictive probability of success in phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pembro</td>
<td>Control</td>
<td></td>
</tr>
<tr>
<td>All HER2-</td>
<td>0.46 (0.34 – 0.58)</td>
<td>0.16 (0.06 – 0.27)</td>
<td>&gt; 99%</td>
</tr>
<tr>
<td>TNBC</td>
<td>0.60 (0.43 – 0.78)</td>
<td>0.20 (0.06 – 0.33)</td>
<td>&gt;99%</td>
</tr>
<tr>
<td>HR+/HER2-</td>
<td>0.34 (0.19 – 0.48)</td>
<td>0.13 (0.03 – 0.24)</td>
<td>&gt;99%</td>
</tr>
</tbody>
</table>

The Bayesian model estimated pCR rates appropriately adjust to characteristics of the I-SPY 2 population. The raw pCR rates (not shown) are higher than the model estimate of 0.604 in TNBC.
Pembrolizumab graduated in all HER2- signatures: Both HR+/HER2- and TN

<table>
<thead>
<tr>
<th>Signature</th>
<th>Estimated pCR rate (95% probability interval)</th>
<th>Probability pembro is superior to control</th>
<th>Predictive probability of success in phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pembro</td>
<td>Control</td>
<td></td>
</tr>
<tr>
<td>All HER2-</td>
<td>0.46 (0.34 – 0.58)</td>
<td>0.16 (0.06 – 0.27)</td>
<td>&gt; 99%</td>
</tr>
<tr>
<td>TNBC</td>
<td>0.60 (0.43 – 0.78)</td>
<td>0.20 (0.06 – 0.33)</td>
<td>&gt;99%</td>
</tr>
<tr>
<td>HR+/HER2-</td>
<td>0.34 (0.19 – 0.48)</td>
<td>0.13 (0.03 – 0.24)</td>
<td>&gt;99%</td>
</tr>
</tbody>
</table>

The Bayesian model estimated pCR rates appropriately adjust to characteristics of the I-SPY 2 population.
The raw pCR rates (not shown) are higher than the model estimate of 0.604 in TNBC.
Pembrolizumab graduated in all HER2- signatures: Both HR+/HER2- and TN

<table>
<thead>
<tr>
<th>Signature</th>
<th>Estimated pCR Rate (95% Probability Interval)</th>
<th>Probability Pembro Superior to Control</th>
<th>Predictive Probability of Success in Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pembro</td>
<td>Control</td>
<td></td>
</tr>
<tr>
<td>HER2-</td>
<td>0.44</td>
<td>0.17</td>
<td>&gt;0.999</td>
</tr>
<tr>
<td></td>
<td>(0.33 – 0.55)</td>
<td>(0.11 – 0.23)</td>
<td></td>
</tr>
<tr>
<td>HR-HER2-</td>
<td>0.60</td>
<td>0.22</td>
<td>&gt;0.999</td>
</tr>
<tr>
<td></td>
<td>(0.44 – 0.75)</td>
<td>(0.13 – 0.30)</td>
<td></td>
</tr>
<tr>
<td>HR+HER2-</td>
<td>0.30</td>
<td>0.13</td>
<td>0.996</td>
</tr>
<tr>
<td></td>
<td>(0.17 – 0.43)</td>
<td>(0.07 – 0.19)</td>
<td></td>
</tr>
</tbody>
</table>

The Bayesian model estimated pCR rates appropriately adjust to characteristics of the I-SPY 2 population. The raw pCR rates (not shown) are higher than the model estimate of 0.604 in TNBC.
pCR Probability Distributions by Signature

**HER2−**
- **Control:** 17%
- **Pembrolizumab:** 44%

**HR−HER2−**
- **Control:** 22%
- **Pembrolizumab:** 60%

- 95% PI: 13% - 30%
- 95% PI: 44% - 75%

**HR+HER2−**
- **Control:** 13%
- **Pembrolizumab:** 30%

- 95% PI: 7% - 19%
- 95% PI: 17% - 43%
## Select treatment-related adverse events

<table>
<thead>
<tr>
<th></th>
<th>Pembrolizumab (n=69)</th>
<th>Control (n=180)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All grades</td>
<td>Grades 3-5</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>7.2 (5)</td>
<td>7.2 (5)</td>
</tr>
<tr>
<td>Neutropenia w/o fever</td>
<td>5.8 (4)</td>
<td>1.4 (1)</td>
</tr>
<tr>
<td>Anemia</td>
<td>27.5 (19)</td>
<td>4.3 (3)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>79.7 (55)</td>
<td>5.8 (4)</td>
</tr>
<tr>
<td>Nausea</td>
<td>73.9 (51)</td>
<td>4.3 (3)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>34.8 (24)</td>
<td>1.4 (1)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>49.3 (34)</td>
<td>7.2 (5)</td>
</tr>
<tr>
<td>Peripheral motor neuropathy</td>
<td>13.0 (9)</td>
<td>1.4 (1)</td>
</tr>
<tr>
<td>Peripheral sensory neuropathy</td>
<td>50.7 (35)</td>
<td>1.4 (1)</td>
</tr>
</tbody>
</table>

From start of treatment to 30 days after surgery (3 months after last dose of pembrolizumab)
Up to 60 days after treatment for those not undergoing surgery
## Select treatment-related adverse events

<table>
<thead>
<tr>
<th></th>
<th>Pembrolizumab (n=69)</th>
<th></th>
<th>Control (n=180)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (n)</td>
<td>All grades</td>
<td>% (n)</td>
<td>All grades</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Grades 3-5</td>
<td></td>
<td>Grades 3-5</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>7.2 (5)</td>
<td>7.2 (5)</td>
<td>6.7 (12)</td>
<td>6.7 (12)</td>
</tr>
<tr>
<td>Neutropenia w/o fever</td>
<td>5.8 (4)</td>
<td>1.4 (1)</td>
<td>1.7 (3)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Anemia</td>
<td>27.5 (19)</td>
<td>4.3 (3)</td>
<td>18.9 (34)</td>
<td>3.9 (7)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>79.7 (55)</td>
<td>5.8 (4)</td>
<td>81.1 (146)</td>
<td>0.6 (1)</td>
</tr>
<tr>
<td>Nausea</td>
<td>73.9 (51)</td>
<td>4.3 (3)</td>
<td>71.7 (129)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>34.8 (24)</td>
<td>1.4 (1)</td>
<td>18.3 (33)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>49.3 (34)</td>
<td>7.2 (5)</td>
<td>37.8 (68)</td>
<td>2.2 (4)</td>
</tr>
<tr>
<td>Peripheral motor neuropathy</td>
<td>13.0 (9)</td>
<td>1.4 (1)</td>
<td>4.4 (8)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Peripheral sensory neuropathy</td>
<td>50.7 (35)</td>
<td>1.4 (1)</td>
<td>59.4 (107)</td>
<td>1.1 (2)</td>
</tr>
</tbody>
</table>

From start of treatment to 30 days after surgery (3 months after last dose of pembrolizumab)
Up to 60 days after treatment for those not undergoing surgery.
## Select treatment-related adverse events

<table>
<thead>
<tr>
<th></th>
<th>Pembrolizumab (n=69)</th>
<th>Control (n=180)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (n)</td>
<td>% (n)</td>
</tr>
<tr>
<td><strong>All grades</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Grades 3-5</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>7.2 (5)</td>
<td>6.7 (12)</td>
</tr>
<tr>
<td>Neutropenia w/o fever</td>
<td>5.8 (4)</td>
<td>1.7 (3)</td>
</tr>
<tr>
<td>Anemia</td>
<td>27.5 (19)</td>
<td>18.9 (34)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>79.7 (55)</td>
<td>81.1 (146)</td>
</tr>
<tr>
<td>Nausea</td>
<td>73.9 (51)</td>
<td>71.7 (129)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>34.8 (24)</td>
<td>18.3 (33)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>49.3 (34)</td>
<td>37.8 (68)</td>
</tr>
<tr>
<td>Peripheral motor neuropathy</td>
<td>13.0 (9)</td>
<td>4.4 (8)</td>
</tr>
<tr>
<td>Peripheral sensory neuropathy</td>
<td>50.7 (35)</td>
<td>59.4 (107)</td>
</tr>
</tbody>
</table>

From start of treatment to 30 days after surgery (3 months after last dose of pembrolizumab)
Up to 60 days after treatment for those not undergoing surgery
Adverse Events of Special Interest (including immune-related toxicities)

<table>
<thead>
<tr>
<th></th>
<th>Pembrolizumab (n=69)</th>
<th>Control (n=180)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (n)</td>
<td>% (n)</td>
</tr>
<tr>
<td></td>
<td>All grades</td>
<td>Grade 3-5</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>8.7 (6)</td>
<td>1.4 (1)</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>4.3 (3)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Adrenal Insufficiency^</td>
<td>8.7 (6)</td>
<td>7.2 (5)</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>2.9 (2)</td>
<td>2.9 (2)</td>
</tr>
<tr>
<td>Pneumonitis</td>
<td>2.9 (2)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Colitis</td>
<td>1.4 (1)</td>
<td>1.4 (1)</td>
</tr>
<tr>
<td>Pruritis</td>
<td>24.6 (17)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

*includes both hyperthyroidism and hypothyroidism
^includes primary and secondary causes of AI
### Adverse Events of Special Interest (including immune-related toxicities)

<table>
<thead>
<tr>
<th></th>
<th>Pembrolizumab (n=69)</th>
<th>Control (n=180)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (n)</td>
<td>% (n)</td>
</tr>
<tr>
<td>All grades</td>
<td></td>
<td></td>
</tr>
<tr>
<td>grade 3-5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>8.7 (6)</td>
<td>0.6 (1)</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>4.3 (3)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Adrenal Insufficiency^</td>
<td>8.7 (6)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>2.9 (2)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Pneumonitis</td>
<td>2.9 (2)</td>
<td>1.1 (2)</td>
</tr>
<tr>
<td>Colitis</td>
<td>1.4 (1)</td>
<td>0.6 (1)</td>
</tr>
<tr>
<td>Pruritis</td>
<td>24.6 (17)</td>
<td>11.1 (20)</td>
</tr>
</tbody>
</table>

*includes both hyperthyroidism and hypothyroidism

^includes primary and secondary causes of AI
Primary and Secondary Adrenal Insufficiency

• Adrenal insufficiency reported in 6 patients
  – At least 3 were related to hypophysitis (secondary AI)
  – 5 presented after completion of AC (10-12 weeks after last pembro dose)
  – 1 presented during pembro treatment (5 weeks after 1\textsuperscript{st} pembro dose)
  – Variable presentation (N/V, fatigue, weakness)
  – Patients on replacement therapy

• Primary and secondary AI are known toxicities of pembrolizumab
  – Rates across all studies are 0.8% and 0.6%

• Due to the toxicities observed, serial screening AM cortisol levels have been incorporated into trial, in addition to ongoing serial thyroid function testing
Conclusions

• Pembrolizumab x 4 cycles plus paclitaxel has graduated for all HER2-signatures studied
  – Near Tripling of the estimated pCR rate in TNBC (60% vs 20%)
  – More than doubling of the estimated pCR rate in HR+/HER2- (34% vs 13%)
  – First agent to graduate in HR+/HER2- signature

• Adrenal insufficiency was observed at a higher rate than previously reported in advanced cancer; pts are doing well on replacement therapy; follow-up of patient outcomes is ongoing

• This is the first report regarding the incidence and time course of immune-mediated toxicities in early stage breast cancer
Future Work

• An experimental arm where pembrolizumab is continued for the anthracycline-based portion of the I-SPY 2 will begin enrollment soon (8 cycle arm)

• I-SPY2 is a biomarker-rich clinical trial with multiple platforms and serial tumor specimens
  – Studies to identify those most likely to benefit or have complications are ongoing
I-SPY 2 TRIAL Study Team

I-SPY 2 Working Group Chairs:
Laura Esserman: Principal Investigator
Don Berry: Principal Investigator, Study Statistician
Angela DeMichele: Co-PI, Site Operations
Doug Yee: Co-PI, Agents
Laura van ‘t Veer: Co-PI, Biomarkers
Fraser Symmans: Co-PI, Pathology
Nola Hylton: Co-PI, Imaging
Michael Hogarth: Co-PI, Informatics
Jane Perlmutter: Lead Advocate, Advocates
Hope Rugo & Richard Schwab: PI/Co-PI, Safety
Michelle Melisko: Co-PI, Quality of Life

Site PIs:
UCSD: Anne Wallace; USC: Julie Lang; Swedish: Erin Ellis;
UMinn: Doug Yee Mayo: Judy Boughey; UCSF: Jo Chien;
Georgetown: Claudine Isaacs U.Chicago: Rita Nanda;
Loyola Chicago: Kathy Albain; U.Colorado: Anthony Elias;
U.Penn: Amy Clark Oregon HSU: Kathleen Kemmer;
UTSouthwestern: Barbara Haley U Alabama: Andres Forero-Torres
Columbia: Kevin Kalinsky; Moffitt: Heather Han;

Sponsor: Quantum Leap Healthcare Collaborative: Dave Mandelkern,
Nancy Lisser, Mike Bankert, Adam Asare, Smita Asare
Funding: Safeway, Bill Bowes, Quintiles, J&J, Genentech, Amgen, Give
Breast Cancer the Boot, Harlans, Side-Out, Avon, Alexandria
Oversight: Anna Barker/ASU, Gary Kellogg/NCI
FDA: Janet Woodcock, Richard Pazdur

I-SPY Program Management Office (PMO)
Exec Director, I-SPY Trial Operations: Smita Asare
Operations Manager: Ruby Singhroo
Kat Steeg, Lorena Kanu, Julie LeDuc, Jill Parker, Reggie Gladney,
Evan Sirchuk
Safety Sausan Abouharb, Linda Doody, Monina Angeles, CCSA
Data Analysis and IT Team
Ashish Sanil, Christina Yau, Adam Asare, Karen Kimura, Garry
Peterson, Amy Wilson
I-SPY 2 Lab, Biomarkers and Translational Research
Lamorna Brown-Swigart, Gillian Hirst, Denise Wolf, Jeff Matthews,
Chip Petricoin and Julie Wulfkuhle
I SPY Imaging Lab: Jessica Gibbs, M Watkins
Business Development: Daniel Dornbusch

I-SPY 2 Agents Committee
Kathy Albain, Christopher Benz, Jo Chien, Amy Clark, Angela
DeMichele, Laura Esserman, Andres Forero-Torres, Teresa Helsten,
Claudine Isaacs, Brian Leyland-Jones, Minetta Liu, Stacy Moulder, Rita
Nanda, Funmi Olopade, John Park, Barbara Parker, Hope
Rugo,, Doug Yee, Paula Pohlmann, Richard Schwab, Patricia
LoRusso, Anthony Elias, Patricia Haugen, Pamela Miunster, Lajos
Pusztai; Heather Beckwith, Larissa Kord (CTEP)

Thank you to the remarkable patients and families,
and all of the investigators, staff, our DSMB and
advocates, past and present, supporting the trial
I-SPY 2 Participating Organizations

Sponsors and Managers
- Quantum Leap
- A Healthcare Collaborative

Funders, Operations
- UCSF
- Novella Clinical
- A Quintiles Company
- SAFEWAY
- Ingredients for life...
- William K. Bowes, Jr. Foundation
- The Biomarkers Consortium

Investigational Agent Providers
- MERCK
- Genentech
- A Member of the Roche Group
- Plexxikon
- abbvie
- Pfizer
- SYNTA Pharmaceuticals
- Puma Biotechnology

Biomarker Device Providers
- OREGON HEALTH & SCIENCE UNIVERSITY
- salesforce
- UCSF
- BERKELEY LAB
- Lawrence Berkeley National Laboratory
-送delnelle MEDICAL
- HOLOGIC
- The Women's Health Company
- George Mason UNIVERSITY
- THERANOSTICS HEALTH
- The Partner of Choice for Personalized Medicine
- agendia™
- decoding cancer